Hiv-associated Lipodystrophy
📧 Sign up to get email alerts when something new happens for Hiv-associated Lipodystrophy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-03-25FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) submitted by Theratechnologies Inc.
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals [Phase 4]
Phase 4 trial update examining changes in weight, body composition and cardiac risk after stopping abacavir in HIV-infected individuals. The…
-
FDA approval · 2024-02-27FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc. This action updates the product's regulator…
-
CLINICAL_TRIALS trial_result · 2019-10-08Clinical Trial Update: HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone) [NA]
A completed clinical trial evaluating classification, measurement, and fat response to the TZD pioglitazone for HIV-associated lipodystrophy…
-
FDA approval · 2019-07-05FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
FDA approved a supplemental application for EGRIFTA WR (tesamorelin) submitted by Theratechnologies Inc., indicating an additional FDA actio…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-01-18FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc., indicating an update or addition to it…
-
CLINICAL_TRIALS trial_result · 2018-05-16Clinical Trial Update: Eplerenone in HIV Associated Abdominal Fat Accumulation [NA]
A clinical trial evaluating eplerenone for HIV-associated abdominal fat accumulation has completed, and the study results were posted on 201…
-
CLINICAL_TRIALS trial_result · 2017-02-06Clinical Trial Update: Rosiglitazone Effect on Mitochondria and Lipoatrophy [Phase 2]
Phase 2 trial evaluating rosiglitazone's effects on mitochondria and lipoatrophy in HIV infections; results posted in 2017.
-
FDA approval · 2015-06-08FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
FDA approves a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc.
-
FDA approval · 2015-02-09FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) submitted by Theratechnologies Inc. This action pertains to the sup…
-
FDA approval · 2014-12-15FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies, related to HIV-associated lipodystrophy.
-
CLINICAL_TRIALS trial_result · 2014-10-13Clinical Trial Update: Effects of Growth Hormone Releasing Hormone in HIV [NA]
A completed clinical trial in HIV evaluated the effects of growth hormone-releasing hormone; results were posted in 2014.
-
FDA approval · 2013-01-07FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc.
-
FDA approval · 2011-11-29FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies.
-
FDA approval · 2010-11-10FDA Approved: EGRIFTA WR — Original Application (Theratechnologies Inc.)
FDA approved EGRIFTA WR (tesamorelin) from Theratechnologies Inc. through an original application. It is indicated for HIV-associated lipody…
-
CLINICAL_TRIALS trial_result · 2010-07-26Clinical Trial Update: Yoga for the Management of HIV-Metabolic Syndromes [Phase 4]
A Phase 4 clinical trial evaluating yoga for HIV-associated metabolic and cardiovascular conditions has completed.
-
CLINICAL_TRIALS trial_result · 2010-03-01Clinical Trial Update: Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy [Phase 3]
A Phase 3 trial evaluating injections of polyacrylamide hydrogel for HIV-associated lipodystrophy has completed.
-
CLINICAL_TRIALS trial_result · 2009-04-02Clinical Trial Update: Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy [Phase 4]
A Phase 4 trial comparing immediate versus deferred injections of poly-L-lactic acid for HIV-associated facial lipoatrophy was terminated.
-
FDA approval ·FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)
The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc.